Details for New Drug Application (NDA): 017531
✉ Email this page to a colleague
NDA 017531 describes TIGAN, which is a drug marketed by King Pharms Llc and Endo Operations and is included in two NDAs. It is available from three suppliers. Additional details are available on the TIGAN profile page.
The generic ingredient in TIGAN is trimethobenzamide hydrochloride. There are six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the trimethobenzamide hydrochloride profile page.
The generic ingredient in TIGAN is trimethobenzamide hydrochloride. There are six drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the trimethobenzamide hydrochloride profile page.
Summary for 017531
| Tradename: | TIGAN |
| Applicant: | King Pharms Llc |
| Ingredient: | trimethobenzamide hydrochloride |
| Patents: | 0 |
Profile for product number 006
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Dec 13, 2001 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
